<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439124</url>
  </required_header>
  <id_info>
    <org_study_id>BPR-PIP-002</org_study_id>
    <nct_id>NCT03439124</nct_id>
  </id_info>
  <brief_title>Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia</brief_title>
  <official_title>A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Paediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the safety and efficacy of ceftobiprole in pediatric patients with
      hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP)
      requiring hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, investigator-blind, active-controlled study to evaluate the safety,
      tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous
      standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients
      aged from 3 months to less than 18 years with HAP or CAP requiring hospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Comparison of adverse event frequencies between treatment groups in the safety population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure at the TOC visit</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Comparison of the clinical cure rates between treatment groups in the intent-to-treat (ITT) and clinically evaluable (CE) populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication at the TOC visit</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Comparison of the microbiological eradication rates between treatment groups in the modified ITT (mITT) and microbiologically evaluable (ME) populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure of pneumonia at study Day 4 and at the EOT visit</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Comparison of cure rates between treatment groups in the ITT and CE populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse at the LFU visit</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Comparison of relapse rates between treatment groups in the ITT, mITT, and CE populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological relapse at the LFU visit</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Comparison of relapse rates between treatment groups in the ITT, mITT and ME populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ceftobiprole plasma concentration</measure>
    <time_frame>Day 3</time_frame>
    <description>Descriptive analysis per sample time point and age group (&lt; 6 years and ≥ 6 years)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <condition>Hospital-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ceftobiprole [HAP]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftobiprole medocaril in Hospital-Acquired Pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftazidime [HAP]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftazidime in Hospital-Acquired Pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftobiprole [CAP]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftobiprole medocaril in Community-Acquired Pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone [CAP]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftriaxone in Community-Acquired Pneumonia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftobiprole medocaril</intervention_name>
    <description>Ceftobiprole medocaril 10 to 20 mg/kg (age-adjusted) IV q8h</description>
    <arm_group_label>Ceftobiprole [HAP]</arm_group_label>
    <arm_group_label>Ceftobiprole [CAP]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Ceftazidime 50 mg/kg IV q8h, up to a maximum of 6 g/day</description>
    <arm_group_label>Ceftazidime [HAP]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>Ceftriaxone 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day</description>
    <arm_group_label>Ceftriaxone [CAP]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight of at least 5 kg

          -  Diagnosis of either hospital-acquired pneumonia or community-acquired pneumonia
             requiring hospitalization

          -  Requirement for IV antibacterial treatment for pneumonia

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Known resistance of the causative pathogen to ceftobiprole or IV standard-of-care
             cephalosporin treatment (± vancomycin)

          -  On mechanical ventilation

          -  Chest trauma with severe lung contusion or flail chest

          -  Acute respiratory distress syndrome

          -  Empyema or lung abscess

          -  Anatomical bronchial obstruction

          -  Active or currently treated pulmonary tuberculosis

          -  Atypical bacterial pneumonia, or viral pneumonia without bacterial superinfection, or
             need for antibiotic coverage with a macrolide

          -  Pertussis, chemical pneumonitis, or cystic fibrosis

          -  Severe immunodeficiency

          -  Significant laboratory abnormalities including: Hematocrit &lt;20%; Absolute neutrophil
             count &lt;0.5x10⁹/L; Platelet count &lt;50x10⁹/L; Alanine aminotransferase, aspartate
             aminotransferase, or bilirubin &gt;5 times the age-specific upper limit of normal;
             Creatinine clearance &lt;50 mL/min/1.73 m²

          -  Use of systemic antimicrobial therapy for more than 24 hours in the 48 hours before
             randomization

          -  History of a previous clinically-relevant hypersensitivity or serious adverse reaction
             to beta lactam antibiotics or to vancomycin

          -  Poorly controlled seizure disorder

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Hamed, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamal Hamed, MD, MPH</last_name>
    <phone>+41 61 567 1588</phone>
    <email>kamal.hamed@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnes Kaelin Aebi, PhD</last_name>
    <phone>+41 61 567 1534</phone>
    <email>agnes.kaelinaebi@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

